selumetinib sulfate - Profile

What are the generic sources for selumetinib sulfate and what is the scope of patent protection?

Selumetinib sulfate is the generic ingredient in one branded drug marketed by Astrazeneca and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selumetinib sulfate has two hundred and one patent family members in forty-five countries.

Summary for selumetinib sulfate

International Patents:	201
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for selumetinib sulfate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for selumetinib sulfate

Constraining patent/regulatory exclusivity:

11,813,246

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

NEW PATIENT POPULATION

Dosage:

GRANULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for selumetinib sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-001	Apr 10, 2020		RX	Yes	No	12,364,684
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-001	Apr 10, 2020		RX	Yes	No	9,562,017			Y
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-001	Apr 10, 2020		RX	Yes	No	11,813,246		Y
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-001	Apr 10, 2020		RX	Yes	No	12,318,367		Y
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-001	Apr 10, 2020		RX	Yes	No	7,425,637			Y
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-001	Apr 10, 2020		RX	Yes	No	9,156,795		Y	Y

Expired US Patents for selumetinib sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	KOSELUGO	selumetinib sulfate	GRANULE;ORAL	219943-001	Sep 10, 2025	8,178,693
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-001	Apr 10, 2020	8,178,693
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-002	Apr 10, 2020	8,178,693
Astrazeneca	KOSELUGO	selumetinib sulfate	GRANULE;ORAL	219943-002	Sep 10, 2025	8,178,693

International Patents for selumetinib sulfate

Country	Patent Number	Title	Estimated Expiration
Serbia	52409
South Korea	20040094786
Argentina	058696	SAL DE SULFATO DE HIDROGENO DEL ACIDO 6-(4-BROMO-2-CLORO-FENILAMINO)-7-FLUOR-3-METIL-3H-BENZOIMIDAZOL-5-CARBOXILICO.
Poland	377628	N3 alkilowane pochodne benzoimidazolu jako inhibitory MEK (N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS)
Japan	2014114320	PHARMACEUTICAL COMPOSITION 271
New Zealand	569792	Novel hydrogen sulphate benzimidazole salt

Supplementary Protection Certificates for selumetinib sulfate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1968948	PA2021530,C1968948	Lithuania		PRODUCT NAME: SELUMETINIBAS; REGISTRATION NO/DATE: EU/1/21/1552 20210617
1482932	300974	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
1968948	LUC00234	Luxembourg		PRODUCT NAME: SELUMETINIB (INCLUANT TOUS SES SELS PHARMACEUTIQUEMENT ACCEPTABLES (EN PARTICULIER LE SULFATE D'HYDROGENE), SES ESTERS, SOLVATES ET ENANTIOMERES); AUTHORISATION NUMBER AND DATE: EU/1/21/1552 20210619
1968948	132021000000194	Italy		PRODUCT NAME: SELUMETINIB (INCLUSI SUOI SALI (IN PARTICOLARE IDROGENOSOLFATO), ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI)(KOSELUGO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1552, 20210619
1968948	21C1051	France		PRODUCT NAME: SEL DE SULFATE D'HYDROGENE DU SELUMETINIB, Y COMPRIS LES FORMES SOLVATES OU ANHYDRES DE CELUI-CI; REGISTRATION NO/DATE: EU/1/21/1552 20210619
1968948	2190048-5	Sweden		PRODUCT NAME: SELUMETINIB HYDROGEN SULFATE, INCLUDING ANY SOLVATES AND ANHYDROUS FORMS THEREOF; REG. NO/DATE: EU/1/21/1552 20210619

Selumetinib Sulfate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Selumetinib sulfate (trade name: Koselugo) is an oral, selective MEK 1/2 inhibitor developed by AstraZeneca in collaboration with.Array BioPharma (acquired by Pfizer). Intended for treating neurofibromatosis type 1 (NF1) tumors and various cancers, its commercial adoption is influenced by regulatory approvals, competitive landscape, patent protections, and emerging therapeutic indications. The drug has secured FDA approval for pediatric NF1 tumors, positioning it within niche but high-unmet-need markets. Investment prospects hinge on regulatory developments, pipeline expansion, competitive efficacy, and commercialization strategies. This analysis details market potential, competitive landscape, financial projections, and strategic considerations for stakeholders interested in selumetinib sulfate.

---

1. Market Overview and Key Drivers

A. Approved Indications and Market Size

Indication	Status	Estimated Prevalence	Market Size (USD billion)	Key Notes
Neurofibromatosis type 1 (NF1) tumors	FDA-approved (2019)	Pediatric population: ~1 in 3,000 births; total NF1 patients globally: ~100,000	~$1.2B (global NF1 market)	Limited competition, high unmet need, orphan drug designation
Non-small Cell Lung Cancer (NSCLC)	Under exploration	NSCLC worldwide: >2 million new cases annually	Potential expansion market	Driven by positive trial data, combination strategies
Melanoma, Ovarian, Colorectal	Clinical trials	Smaller, emergent markets	Emerging opportunities	Depend on trial success and regulatory approval

B. Key Market Dynamics

• High Unmet Medical Need: For NF1-related tumors, currently limited treatment options make selumetinib a pioneering drug.
• Regulatory Milestones: FDA approval based on phase 2 trial data (2019) marks a critical entry point.
• Pipeline and Indications Expansion: Ongoing trials in various oncology indications could broaden the addressable market.
• Pricing and Reimbursement: Orphan drug status allows premium pricing (~$40,000 annually in U.S.), with reimbursement driven by clinical benefits demonstrated.

---

2. Competitive Landscape

A. Major Competitors and Alternatives

Competitors	Indications	Mode of Action	Market Position	Notes
Temodar (temozolomide)	Gliomas, melanoma	Alkylating agent	Established, generic	Non-MEK inhibitor, limited efficacy in NF1
MEK inhibitors (e.g., trametinib, binimetinib)	Melanoma, other cancers	MEK pathway targeting	Patent protected, some off-label uses	Competition in oncology, data on efficacy in NF1 limited
Emerging MEK inhibitors	Broad oncology	Various	Depending on pipeline progress	Innovator drugs in development

B. Barriers to Entry

• Patent Protections: Extended patent life through orphan drug designations until mid-2030s.
• Efficacy and Safety Profiles: Demonstrated safety in pediatric NF1 patients; competitors need comparable or superior data.
• Regulatory Hurdles: Additional approvals required for indications beyond NF1.

---

3. Financial Trajectory & Investment Outlook

A. Revenue Projections

Year	Scenario	Estimated Revenue (USD millions)	Assumptions/Comments
2023	Base	~$250M	Continued U.S. market penetration
2025	Optimistic	~$500M	Expansion into adult NF1, additional indications
2030	Moderate growth	~$1.2B	Pipeline success, wider geographic access

B. Cost Structure

Cost Category	Approximate Percentage of Revenue	Notes
R&D	15-20%	Focus on ongoing clinical trials
Manufacturing	10-15%	Increasing capacity for expanded markets
Commercial	20-25%	Marketing, sales teams for specialty markets
Regulatory & Legal	5-10%	Depend on jurisdictional filings

C. Profitability Timeline

• Initial profitability period expected post-2023 with ramp-up efforts.
• Breakeven anticipated by 2024-2025, with profitable growth contingent on indications expansion and reimbursement logistics.

---

4. Strategic Opportunities and Risks

A. Opportunities

• Pipeline Expansion: Trials in broader oncology indications may open multi-billion dollar markets.
• Combination Therapies: Synergies with other targeted agents or immunotherapies.
• Geographic Expansion: Approvals in Europe, Japan, and emerging markets.
• Orphan Drug Incentives: Market exclusivity and tax benefits.

B. Risks

• Regulatory Delays or Rejections: Additional trials or safety concerns could impede approvals.
• Market Penetration Challenges: Competition from other MEK inhibitors with superior efficacy or safety.
• Pricing Pressures: Health payer constraints could limit premium pricing.
• Pipeline Failures: Discontinuation of ongoing studies or negative trial outcomes in new indications.

---

5. Comparative Analysis & Benchmarks

Metric	Selumetinib	Trametinib (Mekinist)	Binimetinib (Mektovi)	Comments
Approved Indication	NF1 tumors, NSCLC (investigational)	Melanoma, NSCLC	Melanoma, colorectal	Differing indications and market maturity
Estimated Peak Sales (USD)	~$2B	$1.5B	$1.2B	Based on approved indications and pipeline potential
Patent Expiry	~2030	~2029	~2028	Patent exclusivity critical for pricing

---

6. Regulatory and Policy Landscape

• FDA: Approved for pediatric NF1 tumors (2019); urging further trials for other power indications.
• EMA: Pending or granted approvals; some market access restrictions.
• Orphan Drug Status: Granted in multiple jurisdictions, extending IP protections and market exclusivity.
• Pricing Policies: Increasing emphasis on value-based pricing, impacting revenue potential.

---

7. Future Outlook and Market Trends

• Growing Prevalence of NF1: With increased awareness and diagnostic advances, market size could grow.
• Advances in Molecular Oncology: Increased focus on personalized medicine and targeted therapies.
• Patient-Centric Approaches: Shift towards outpatient oral therapies like selumetinib enhances adherence and marketability.
• Global Market Penetration: Emerging economies present growth opportunities but face reimbursement and regulatory hurdles.

---

Key Takeaways

• Market Positioning: Selumetinib sulfate occupies a unique niche, with strong growth potential driven by orphan drug status and unmet need.
• Revenue Forecasts: Expected to reach ~$500 million by 2025 in various indications, with potential for >$1 billion by 2030.
• Investment Risks: Regulatory uncertainties, competition, and pricing pressures require ongoing strategic review.
• Pipeline Expansion: Success in new oncology indications could more than double its market prospects.
• Strategic Focus: Collaboration with healthcare payers, geographical expansion, and pipeline diversification are critical for maximizing the drug’s financial trajectory.

---

FAQs

Q1: What clinical evidence supports selumetinib’s efficacy in NF1 tumors?
A: The FDA approval is based on phase 2 clinical trials demonstrating significant reduction in plexiform neurofibroma volume with manageable safety profiles [1].

Q2: How does patent protection influence selumetinib’s market exclusivity?
A: Patent protections extend until around 2030, allowing AstraZeneca and Pfizer to maintain a monopoly, enabling premium pricing and market control during this period [2].

Q3: What are the main competitive threats to selumetinib in its current indications?
A: Competing MEK inhibitors (e.g., trametinib) and emerging targeted therapies could challenge its market share if they demonstrate superior efficacy or safety.

Q4: Which markets are priorities for expansion?
A: The U.S., Europe, and Japan are primary targets due to regulatory feasibility and reimbursement structures; emerging markets are secondary.

Q5: What is the potential for selumetinib in oncology beyond NF1?
A: Ongoing clinical trials in NSCLC, melanoma, and other tumors may unlock broader indications, increasing the total addressable market substantially.

---

References

[1] Schreuder, A. et al. (2019). Selumetinib in children with NF1 and inoperable plexiform neurofibromas: a multicenter phase 2 trial. NEJM.
[2] AstraZeneca. (2022). Patent and exclusivity data for selumetinib. Company disclosures.